Fresh Recalls

FDAClass II · Drug · Recall D-0596-2026 · Recalled June 24, 2026

Buprenorphine HCl recall — Par Health USA, LLC

Agency report date: June 24, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Buprenorphine HCl
Company / brand
Par Health USA
Lot / serial / date codes
Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027
Distribution
Nationwide in the USA.
Agency product description and boundaries

Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Crystallization; identified as Buprenorphine free base

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class II: may cause temporary or medically reversible health consequences.

Affected product: Buprenorphine HCl

3. Open the official notice or contact

Official recall ID
D-0596-2026
Brand
Par Health USA
Classification
Class II
Units affected
46,334 units
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Rochester, MI, United States
Firm address
870 Parkdale Rd, 48307-1740

Identifying details (verbatim from the notice)

Product codes / lots
Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027
Distribution
Nationwide in the USA.
Firm notified the public via
Letter
FDA event ID
99237
Recall initiated
June 12, 2026
FDA classified
June 17, 2026
FDA report date
June 24, 2026
Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked September 7, 2026 at 6:00 AM UTC. Record retrieved September 7, 2026 at 6:00 AM UTC.

Report a data error on this page